Back to search results

Brief Pain Reprocessing Therapy for Chronic Lower Back Pain in Veterans

This study is investigating Brief Pain Reprocessing Therapy (BPRT) as a potential treatment for Veterans experiencing chronic lower back pain (CLBP). BPRT is a behavioral intervention delivered remotely via Zoom. The study aims to see if this therapy is acceptable and practical for Veterans, and if it's safe. You might be able to join if you are a Veteran, 18 years or older, have had low back pain for over 6 months, and can read and speak English with internet access. The study plans to enroll 50 participants. Currently, the recruitment status is unclear.

Study design
This interventional study plans to enroll 50 participants. It is not specified if it's randomized or blinded.
What's involved
You would participate in three 90-minute behavioral intervention sessions over 3 weeks, complete daily assessments for 35 days, and fill out questionnaires.
Compensation
Not stated in the trial record.
Follow-up
You will complete study questionnaires at 1, 2, 3, and 6 months after attending the behavioral sessions.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06771713

Brief Pain Reprocessing Therapy in Veterans

Active, Not Recruiting
NAAges 18+InterventionalTreatment
University of Michigan
~50 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:Brief Pain Reprocessing Therapy (BPRT)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Acceptability of and satisfaction with treatment base on the mean scores on the Treatment Evaluation Inventory (TEI-SF) assessed at T5 (approximately day 35)
Measured over Approximately day 35 (post treatment)
+7 more outcomes measured

Conditions

Chronic Lower Back Pain (CLBP)

Explore related trials

Lower Back Pain

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • John Sturgeon, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Low back pain that has lasted greater than 6 months, with pain on at least half of these days
Must provide verification of being an Armed Service Veteran.
Able to read, write and speak English
Internet access and audio-conferencing capability (e.g., Zoom meetings by phone or computer) in the home

Exclusion

Self-reported evidence of a separate medical condition (e.g., rheumatoid arthritis), acute injury in the past 12 months (e.g., self-reported spinal fracture), self-reported loss of bowel or bladder control in the past year (which may indicate presence of cauda equina syndrome), or evidence of presence of a metastasizing cancer requiring treatment
Pending surgical procedures or interventional therapies (e.g., spinal injections) within the next 12 months
Confirmed/suspected pregnancy
Evidence of other conditions that may preclude participants from understanding or being able to participate in study procedure (e.g., schizoaffective disorder, suspected or diagnosed dementia)
Currently receiving cognitive-behavioral therapy or other psychological therapies for pain
Open litigation in the past 1 year, as assessed in preliminary study screening.
Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.

What this trial measures

  • Acceptability of and satisfaction with treatment base on the mean scores on the Treatment Evaluation Inventory (TEI-SF) assessed at T5 (approximately day 35)Approximately day 35 (post treatment)

    The TEI-SF is a validated instrument for behavioral interventions. There are 9 questions that participants answer from 1 (strongly disagree) - 5 (strongly agree) with a range of (9-45) with a higher score indicating greater acceptability. Scores at 27 or above will denote moderate acceptability of the intervention.

  • Feasibility will be accessed by participant adherenceUp to approximately day 35 (post treatment)

    Adherence to the intervention will be determined by at least 80% attendance of intervention sessions, completion of daily assessment, and self-reported adherence to home-base exposure practices, completion of pre/post session and pre/post interventions.

  • Feasibility will be accessed by feedback from the Qualitative InterviewsApproximately day 35 (post treatment)

    Qualitative Interviews will occur after conclusion of the intervention period to address areas of improvement in future iterations of the intervention.

  • Safety will be assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS 29) pain intensityBaseline, up to day 35 post treatment

    There is 1 question that participants will answer pain level from 0 (not at all) - 10 (worst pain imaginable).

  • Safety will be assessed by the PROMIS Depression scaleBaseline, up to day 35 post treatment

    Participants will answer 4 questions 1 (never) -5 (always). There is a range of scores from 4-20 with a higher score indicating higher levels of depression.

  • Safety will be assessed by the PROMIS Anxiety scaleBaseline, up to day 35 post treatment

    Participants will answer 4 questions 1 (never) -5 (always). There is a range of scores from 4-20 with a higher score indicating higher levels of anxiety.

  • Safety will be assessed by the Patient Global Impression of Change (PGIC)Baseline, up to day 35 post treatment

    There is 1 question that participants will select from 1 (very much improved) - 7 (very much worse).

  • Safety assessed by the number of Adverse events and Serious adverse events T6 (Day 60) - T9 (Day 210)T6 (Day 60) - T9 (Day 210)

    Adverse events will be classified as serious or non-serious (per protocol). These will be assessed by items such as death, life-threatening event, hospitalization, emergency room visits, persistent or significant disability/incapacity, suicide plans or attempts.